Anixa Biosciences (NASDAQ:ANIX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Up 4.6 %

Shares of ANIX opened at $3.20 on Tuesday. The company has a market cap of $102.98 million, a price-to-earnings ratio of -8.20 and a beta of 0.84. Anixa Biosciences has a twelve month low of $2.14 and a twelve month high of $5.13. The company has a 50 day moving average of $3.25 and a two-hundred day moving average of $2.99.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Friday, September 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, sell-side analysts expect that Anixa Biosciences will post -0.42 EPS for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in ANIX. Concorde Asset Management LLC purchased a new position in shares of Anixa Biosciences during the second quarter worth $31,000. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences during the third quarter worth $34,000. Nations Financial Group Inc. IA ADV raised its holdings in shares of Anixa Biosciences by 50.0% during the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock worth $50,000 after purchasing an additional 7,500 shares during the last quarter. Westside Investment Management Inc. raised its holdings in shares of Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Finally, Tyler Stone Wealth Management raised its holdings in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares during the last quarter. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.